GLP 1 News and Research

RSS

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as measured in a post-trial analysis of blood samples.

22 Jun 2010

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist. Designed and developed at the Zydus Research Centre using a unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule.

21 Jun 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.

18 Jun 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.

18 Jun 2010

Roche implements risk mitigation plan in taspoglutide Phase III programme

Ipsen, a global biopharmaceutical group, today announced that its partner Roche today announced the implementation of a risk mitigation plan in the taspoglutide Phase III programme. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.

18 Jun 2010

Helix BioPharma third-quarter revenues increase 20.6%

Helix BioPharma Corp. today announced financial results for the third quarter ended April 30, 2010.

11 Jun 2010

MicroConstants adds second Waters Xevo TQ MS system

MicroConstants, Inc., a bioanalytical and pharmacokinetic-specialty Contract Research Organization (CRO) in San Diego, California, announces the continued expansion of its bioanalytical capacity through the addition of a second Waters Xevo TQ MS system. The CRO has also appointed a new East Coast business development manager to actively pursue new business opportunities in that region.

10 Jun 2010

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen Corporation today reported results for the fourth quarter and fiscal year 2010, ended March 31, 2010. Total revenue for the year was $20,971,000 compared to total revenue of $29,362,000 for fiscal year 2009 ended March 31, 2009.

9 Jun 2010

Particle Sciences adds Dried Blood Spot Analysis capability to Analytic Services offerings

Particle Sciences has expanded its Bioanalytic Service's offerings to include Dried Blood Spot LC/MS/MS analysis (DBS). DBS is a growing area of interest because of its advantages in sample collection, stability, and simplified storage requirements. By using DBS, sample collection and processing is greatly simplified resulting in decreased costs, increased safety and greater comfort for test subjects.

4 Jun 2010

LAB Research's Canadian laboratory receives OECD-GLP compliance status

LAB Research Inc., a Canadian-based global non-clinical contract research organization, today announced that its Canadian laboratory has received a Good Laboratory Practices recognition from the Standards Council of Canada.

2 Jun 2010

Health Canada approves Victoza for treatment of adults with type 2 diabetes

Diabetes is growing at an alarming rate in Canada, with an estimated 3.7 million people expected to be diagnosed by 2020. It is a progressive disease that, if not properly monitored and managed over time, will lead to serious long term complications. Canadians now have a novel treatment available to help them maintain optimal blood glucose levels. Health Canada has approved Victoza (liraglutide), the first GLP-1 analogue, for once-daily administration for the treatment of adults with type 2 diabetes to improve glycemic control in combination with metformin or metformin and a sulfonylurea.

27 May 2010

Emisphere Technologies first-quarter net loss increases to $18.5 million

Emisphere Technologies, Inc. today announced its financial results for the first quarter 2010.

17 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

6 May 2010

Whole grain barley products with low glycemic response provide favourable metabolic benefits

Evidence from observational studies indicates that diets rich in whole grain reduce risk of obesity and other diseases related to the metabolic syndrome e.g. type 2 diabetes and cardio-vascular disease. The mechanisms involved are only partially elucidated. Work within HEALTHGRAIN has revealed novel insights regarding some potential mechanisms.

6 May 2010

Diets rich in whole grain reduce risk of obesity and other diseases related to metabolic syndrome

5 May 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

The Scripps Research Institute has been awarded a $1.3 million grant by the National Institutes of Health (NIH) to develop a series of tests at its Florida campus to help explore the potential of a protein that has emerged as a highly attractive target for the treatment of obesity and Type 2 diabetes.

3 May 2010

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Ipsen, a global biopharmaceutical group, today announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence. Taspoglutide originating from Ipsen's research is developed by Roche.

29 Apr 2010

Charles River Laboratories International, WuXi PharmaTech sign definitive agreement to combine

Charles River Laboratories International, Inc., a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech, a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion.

26 Apr 2010

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.

24 Apr 2010

GLP 1 News and Research

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Roche implements risk mitigation plan in taspoglutide Phase III programme

Helix BioPharma third-quarter revenues increase 20.6%

MicroConstants adds second Waters Xevo TQ MS system

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Particle Sciences adds Dried Blood Spot Analysis capability to Analytic Services offerings

LAB Research's Canadian laboratory receives OECD-GLP compliance status

Health Canada approves Victoza for treatment of adults with type 2 diabetes

Emisphere Technologies first-quarter net loss increases to $18.5 million

Transition Therapeutics reports increased revenue in third-quarter 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Whole grain barley products with low glycemic response provide favourable metabolic benefits

Diets rich in whole grain reduce risk of obesity and other diseases related to metabolic syndrome

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Charles River Laboratories International, WuXi PharmaTech sign definitive agreement to combine

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News